CMND Clearmind Medicine Inc.

Nasdaq clearmindmedicine.com


$ 0.66 $ -0.22 (-32.11 %)    

Tuesday, 11-Nov-2025 19:59:42 EST
QQQ $ 622.49 $ 0.90 (0.15 %)
DIA $ 479.63 $ 5.34 (1.13 %)
SPY $ 683.37 $ 2.90 (0.43 %)
TLT $ 89.91 $ 0.01 (0.01 %)
GLD $ 380.58 $ -0.09 (-0.02 %)
$ 0.4585
$ 0.67
$ 0.54 x 1,500
$ 0.67 x 153
$ 0.43 - $ 0.68
$ 0.43 - $ 2.18
11,061,883
na
nm
$ 0.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 clearmind-medicine-completes-first-patient-cohort-in-phase-iiia-trial-of-meai-based-cmnd-100-for-alcohol-use-disorder

Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion...

 why-is-clearmind-stock-down-today

Shares of Clearmind Medicine Inc. (NASDAQ: CMND) are falling Friday after the clinical-stage biotech company shared a key updat...

 clearmind-medicine-receives-nasdaq-delisting-notification

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech co...

 clearmind-expands-meai-patent-protection-with-new-south-korea-filing-advancing-global-depression-treatment-strategy

Patent expands MEAI's global intellectual property protection as Clearmind advances clinical development and commercializat...

 clearmind-medicine-says-last-patient-of-first-cohort-in-phase-iiia-clinical-trial-evaluating-cmnd-100-receives-treatment-fda-approved-clinical-protocol

Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion...

 clearmind-medicine-enrolls-last-patient-for-first-cohort-of-phase-iiia-clinical-trial-evaluating-cmnd-100-proprietary-meai-based-oral-drug-candidate-for-aud-treatment

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

Core News & Articles

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusi...

Core News & Articles

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

 clearmind-medicine-enters-10m-convertible-note-agreement-with-institutional-investors-begins-with-555k-issuance-at-500k-purchase-price

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

Core News & Articles

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

 clearmind-medicine-receives-irb-approval-from-hadassah-medical-center-jerusalem-for-ongoing-phase-12a-clinical-trial-evaluating-cmnd-100-proprietary-meai-based-oral-drug-candidate-for-treatment-of-aud

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

Core News & Articles

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusi...

 clearmind-medicine-completes-site-initiation-at-tel-aviv-sourasky-medical-center-for-phase-iiia-clinical-trial-evaluating-cmnd-100-proprietary-oral-drug-candidate-for-aud

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION